Developer docs
API playgroundTry for free, no card

Search company profiles

X-Chem

Full company profile

uuid0004vwj

Namestring
X-Chem
Legal namestring
X-Chem, Inc.
Websiteurl
x-chemrx.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

X-Chem is a privately held biotechnology company founded in 2009 and headquartered in Waltham, Massachusetts, that operates as an integrated small-molecule drug discovery partner to pharmaceutical and biotechnology companies. The company's core technology is a proprietary DNA-Encoded Library (DEL) platform built around libraries exceeding 100 billion compounds, supplemented by medicinal and synthetic chemistry, computational sciences, and AI/ML capabilities under its Chemomics approach. X-Chem delivers discovery outcomes through tiered engagement models: DELcore (full-service discovery partnerships), DELflex (flexible DEL access bundles), and DELability (low-cost tractability assessments), alongside modular milestone-driven programs branded HitBuilder, LeadBuilder, and CandidateBuilder that span hit identification through candidate nomination.

The company monetizes its platform through four revenue streams: fee-for-service drug discovery programs, strategic collaborations with biopharma partners, DEL platform enablement and technology transfer (licensing/royalty economics), and direct sales of ReadiDEL libraries and ReadiBLOX building blocks to partners conducting screening internally. Customer segments span large pharmaceutical companies (Roche, AstraZeneca, AbbVie), mid-market biotech (Enko, Tonix, Kymera), early-stage biotech (Montara Therapeutics, Cube Biotech), academic core facilities, and use-case-specific segments such as neuroscience- and oncology-focused companies. X-Chem reports cumulative outputs of 18 clinical candidates since 2016, 100+ licensed programs, 700+ novel series, >200 billion molecules screened, and >30 challenging target classes addressed. The company operates approximately 200 professional and research staff across Waltham, Montreal, and Budapest, and owns three wholly owned subsidiaries acquired in 2021: IntelliSyn Pharma (medicinal chemistry), ComInnex (European synthetic chemistry), and Glamorous AI (DEL-powered AI services).

Short descriptiontext

X-Chem is a privately held biotechnology company that provides integrated small-molecule drug discovery services to pharmaceutical and biotech clients using a proprietary DNA-Encoded Library (DEL) platform, medicinal chemistry, computational sciences, and AI/ML.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
DNA-encoded library screening, drug discovery services, medicinal chemistry services, small molecule discovery, hit identification services
Industry3 codes
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Drug Discovery Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Discovery Services
TypeProfessional Services
Description

Fee-for-service drug discovery programs including DEL screening, medicinal chemistry, and computational sciences structured as modular, milestone-driven project engagements (HitBuilder, LeadBuilder, CandidateBuilder)

2Strategic Collaborations
TypeLicensing Royalties
Description

Deeply integrated discovery partnerships with biopharma companies providing exclusive or shared discovery outcomes

businesswire.com
3DEL Platform Enablement
TypeLicensing Royalties
Description

Technology transfer programs enabling partners to conduct DEL screening internally using ReadiDEL libraries and X-Chem's informatics tools

4Research Products
TypeOne Time License
Description

Sale of ReadiDEL libraries and ReadiBLOX building blocks for internal DEL screening operations

Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales
Pricing details4 tiers
1DELcore - Full-service discovery partnership
ModelOtherBilling cadenceMulti-year contract
Notes

Comprehensive platform access with expert support; pricing determined by scope and milestone structure

2DELflex - Flexible DEL access bundle
ModelSubscriptionBilling cadenceAnnual
Notes

Bundled DEL access with transparent pricing and complete data access; optional follow-on chemistry

3DELability - Feasibility assessment
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Low-cost target tractability validation before full investment

4Platform Enablement - Technology transfer
ModelOtherBilling cadenceMulti-year contract
Notes

Training and access to ReadiDELs and informatics tools for internal DEL operations

GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1ReadiDEL
Description

DNA-encoded library products ready for screening, including over 40 specialized libraries totaling more than 15 billion compounds

x-chemrx.com
+5 more records
Core offering1 text field

X-Chem provides DNA-encoded library (DEL) screening-based drug discovery services combined with medicinal chemistry, computational sciences, and AI/ML capabilities. The company offers modular milestone-driven programs (HitBuilder, LeadBuilder, CandidateBuilder), fee-for-service packages (DELcore, DELflex, DELability), platform enablement technology transfers, and research products (ReadiDEL libraries, ReadiBLOX building blocks) to help pharmaceutical and biotechnology companies identify and optimize small molecule drug candidates from hit identification through clinical candidate nomination.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 18 clinical candidates since 2016
+6 more records
Product overview1 text field

X-Chem is a DEL technology pioneer offering an integrated drug discovery platform built around DNA-encoded library (DEL) screening as the core engine. The platform comprises multiple tiers (DELcore, DELflex, DELability) for hit identification, augmented by HITMiner AI/ML analytics and the Chemomics approach for data-driven decision making. Downstream services include ReadiDEL and ReadiBLOX research products, Computational Sciences, and Medicinal & Synthetic Chemistry. Modular programs (HitBuilder, LeadBuilder, CandidateBuilder) provide milestone-driven pathways from screening through candidate nomination. The company also offers Platform Enablement for partners building internal DEL capabilities.

Product and service12 records
1DELcore
CategoryDrug Discovery Platform
2DELflex
CategoryDrug Discovery Platform
3DELability
CategoryDrug Discovery Platform
4Covalent Irreversible DEL
CategoryDrug Discovery Platform
5ReadiDEL
CategoryResearch Products
6ReadiBLOX
CategoryResearch Products
7Chemomics
CategoryDrug Discovery Platform
8Computational Sciences
CategoryDiscovery Services
9Medicinal & Synthetic Chemistry
CategoryDiscovery Services
10HitBuilder
CategoryEngagement Programs
11LeadBuilder
CategoryEngagement Programs
12CandidateBuilder
CategoryEngagement Programs
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-20
Description

Strategic collaboration to enhance hit identification capabilities for drug discovery. Combines Charles River's existing drug discovery services with X-Chem's DNA-encoded library technology to support biopharma research and accelerate therapeutic discovery. Partnership aims to support hundreds of discovery programs.

Strategic tierCoreTypeOthersAnnounced on2021-10-28
Description

X-Chem acquired ComInnex, a European provider of synthetic chemistry services and technologies to support early-stage drug discovery. Acquisition expanded X-Chem's global capacity, service offerings, and expertise in innovative chemistry solutions for biopharma clients.

Strategic tierCoreTypeOthersAnnounced on2021-10-28
Description

X-Chem acquired Glamorous AI, adding the industry's only DEL-powered AI service for early-stage drug discovery to its portfolio.

4IntelliSyn Pharma
Strategic tierCoreTypeOthersAnnounced on2021-01-01
Description

X-Chem acquired IntelliSyn in January 2021, establishing hit-to-lead service capabilities including medicinal chemistry.

x-chemrx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration for neurological disease drug discovery. Leveraging brain-specific pharmacology platform, Montara works with X-Chem for next-generation therapies including dementia treatments. Based on successful prior collaboration with Mitokinin (acquired by AbbVie in 2023).

Strategic tierCoreTypeTechnology or Integration
Description

DEL enablement partnership allowing Roche to operate DEL synthesis and screening internally. Roche/Genentech report indicated DEL accounted for ~30% of novel internally generated leads in 2019.

Strategic tierCoreTypeTechnology or Integration
Description

Long-standing DEL collaboration with X-Chem screening many targets from AZ portfolio. Technology transfer enabled AZ to operate DEL synthesis and screening internally, providing flexibility for early-stage research deployment.

Strategic tierCoreTypeTechnology or Integration
Description

Multi-year collaboration culminating in successful technology enablement, empowering Enko to operate DEL platform internally. Projects have successfully progressed to include many high-potential products.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on ligand generation for WD40 repeat-containing proteins. Large-scale multiplexed DEL selection followed by ML model training identified active compounds for 7 out of 16 previously unliganded targets.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration using DEL data for machine learning published in August 2020. Combined DEL screening with ML for target class ligandability evaluation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on WD40 repeat protein targets using DEL selection and machine learning approaches.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration on discovery and optimization of macrocycles targeting Mcl-1 oncology target, demonstrating acceptable permeability and high potency.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on IL-17 inhibitors with DEL-generated SAR and co-crystal structural information leading to compound with good PK properties and potent animal model efficacy.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration on development of noncovalent inhibitors for SARS-CoV-2 Mpro using DEL screening and macrocyclization strategy, achieving 10-fold potency improvement.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

DEL screening collaboration where hits demonstrated in vivo efficacy in mouse model for tuberculosis.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Smaller discovery CROs focused on fragment- and structure-based hit identification for biotech. Representative of the emerging-player tier of CROs that compete with X-Chem's HitBuilder and LeadBuilder programs on price for early-stage biotech.

TypeDirect peer
Description

Symeres is a European CRO specializing in medicinal chemistry, custom synthesis and discovery services. Comparable to X-Chem's medicinal and synthetic chemistry offering and an existing collaboration partner on macrocycle discovery programs.

TypeDirect peer
Description

HitGen is the original DNA-encoded library (DEL) pioneer and operates a directly comparable DEL screening and small-molecule discovery services business, including DEL library products and partnered programs with global pharma. Most direct competitor to X-Chem's core DEL platform.

TypeEmerging player
Description

Domainex is a UK-based CRO offering integrated drug discovery including hit identification, medicinal chemistry and computational services. Comparable to X-Chem's integrated service model for biotech clients, particularly in the European market.

TypeBroad incumbent
Description

Evotec is a global drug discovery CRO offering end-to-end discovery and development services including DEL-based screening. Overlaps with X-Chem across hit identification, medicinal chemistry and integrated drug discovery but at much broader scale.

TypeDirect peer
Description

Philochem is a Swiss-based DEL screening provider and one of the early commercial DEL technology developers. Competes head-to-head with X-Chem in DEL-based hit identification for European pharma and biotech clients.

7Nuevolution (Amgen)
TypeBroad incumbent
Description

Nuevolution was an early DEL competitor acquired by Amgen in 2016; its DEL capability is now embedded inside Amgen's internal discovery engine. Relevant comparable because it demonstrates how DEL platforms are absorbed into large-pharma in-house operations, a key dynamic for X-Chem.

TypeDirect peer
Description

Vipergen is a DEL-technology focused CRO offering DNA-encoded library screening and hit identification services to pharma and biotech. Closely comparable technology stack and customer base to X-Chem's DELcore and DELflex offerings.

TypeBroad incumbent
Description

WuXi AppTec is a global CRO/CDMO offering DEL-enabled drug discovery alongside a much broader portfolio of chemistry, biology and manufacturing services. Overlaps with X-Chem in DEL screening but typically priced more aggressively and bundled with downstream development services.

TypeBroad incumbent
Description

Charles River is a large CRO with an end-to-end drug discovery and safety assessment portfolio and is now X-Chem's strategic distribution partner. Overlaps with X-Chem on early discovery services but also serves as a route to market for X-Chem's DEL platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

X-Chem

Contract Drug Discovery Servicesx-chemrx.com

X-Chem is a privately held biotechnology company that provides integrated small-molecule drug discovery services to pharmaceutical and biotech clients using a proprietary DNA-Encoded Library (DEL) platform, medicinal chemistry, computational sciences, and AI/ML.

What X-Chem does

X-Chem is a privately held biotechnology company founded in 2009 and headquartered in Waltham, Massachusetts, that operates as an integrated small-molecule drug discovery partner to pharmaceutical and biotechnology companies. The company's core technology is a proprietary DNA-Encoded Library (DEL) platform built around libraries exceeding 100 billion compounds, supplemented by medicinal and synthetic chemistry, computational sciences, and AI/ML capabilities under its Chemomics approach. X-Chem delivers discovery outcomes through tiered engagement models: DELcore (full-service discovery partnerships), DELflex (flexible DEL access bundles), and DELability (low-cost tractability assessments), alongside modular milestone-driven programs branded HitBuilder, LeadBuilder, and CandidateBuilder that span hit identification through candidate nomination.

The company monetizes its platform through four revenue streams: fee-for-service drug discovery programs, strategic collaborations with biopharma partners, DEL platform enablement and technology transfer (licensing/royalty economics), and direct sales of ReadiDEL libraries and ReadiBLOX building blocks to partners conducting screening internally. Customer segments span large pharmaceutical companies (Roche, AstraZeneca, AbbVie), mid-market biotech (Enko, Tonix, Kymera), early-stage biotech (Montara Therapeutics, Cube Biotech), academic core facilities, and use-case-specific segments such as neuroscience- and oncology-focused companies. X-Chem reports cumulative outputs of 18 clinical candidates since 2016, 100+ licensed programs, 700+ novel series, >200 billion molecules screened, and >30 challenging target classes addressed. The company operates approximately 200 professional and research staff across Waltham, Montreal, and Budapest, and owns three wholly owned subsidiaries acquired in 2021: IntelliSyn Pharma (medicinal chemistry), ComInnex (European synthetic chemistry), and Glamorous AI (DEL-powered AI services).

X-Chem firmographics

Firmographics
Name
X-Chem
Legal name
X-Chem, Inc.
Website
https://x-chemrx.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
X-Chem is a privately held biotechnology company that provides integrated small-molecule drug discovery services to pharmaceutical and biotech clients using a proprietary DNA-Encoded Library (DEL) platform, medicinal chemistry, computational sciences, and AI/ML.
Ownership category
akta.pro rank

X-Chem industry classification

Industry
Product category
Contract Drug Discovery Services
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAL
Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • DNA-encoded library screening
  • Drug discovery services
  • Medicinal chemistry services
  • Small molecule discovery
  • Hit identification services

Where X-Chem is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices3 records

Markets served

X-Chem business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

  1. Drug Discovery Services: Fee-for-service drug discovery programs including DEL screening, medicinal chemistry, and computational sciences structured as modular, milestone-driven project engagements (HitBuilder, LeadBuilder, CandidateBuilder)
  2. Strategic Collaborations: Deeply integrated discovery partnerships with biopharma companies providing exclusive or shared discovery outcomes
  3. DEL Platform Enablement: Technology transfer programs enabling partners to conduct DEL screening internally using ReadiDEL libraries and X-Chem's informatics tools
  4. Research Products: Sale of ReadiDEL libraries and ReadiBLOX building blocks for internal DEL screening operations

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDELcore - Full-service discovery partnership
SubscriptionAnnualDELflex - Flexible DEL access bundle
Usage-basedPay-as-you-goDELability - Feasibility assessment
OtherMulti-year contractPlatform Enablement - Technology transfer

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

X-Chem product offering

Product offering

Core offering

X-Chem provides DNA-encoded library (DEL) screening-based drug discovery services combined with medicinal chemistry, computational sciences, and AI/ML capabilities. The company offers modular milestone-driven programs (HitBuilder, LeadBuilder, CandidateBuilder), fee-for-service packages (DELcore, DELflex, DELability), platform enablement technology transfers, and research products (ReadiDEL libraries, ReadiBLOX building blocks) to help pharmaceutical and biotechnology companies identify and optimize small molecule drug candidates from hit identification through clinical candidate nomination.

Product overview

X-Chem is a DEL technology pioneer offering an integrated drug discovery platform built around DNA-encoded library (DEL) screening as the core engine. The platform comprises multiple tiers (DELcore, DELflex, DELability) for hit identification, augmented by HITMiner AI/ML analytics and the Chemomics approach for data-driven decision making. Downstream services include ReadiDEL and ReadiBLOX research products, Computational Sciences, and Medicinal & Synthetic Chemistry. Modular programs (HitBuilder, LeadBuilder, CandidateBuilder) provide milestone-driven pathways from screening through candidate nomination. The company also offers Platform Enablement for partners building internal DEL capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • ReadiDEL: DNA-encoded library products ready for screening, including over 40 specialized libraries totaling more than 15 billion compounds
  • ReadiBLOX
  • HitBuilder
  • LeadBuilder
  • CandidateBuilder
  • Chemomics

Products and services

  • DELcore
  • DELflex
  • DELability
  • Covalent Irreversible DEL
  • ReadiDEL
  • ReadiBLOX
  • Chemomics
  • Computational Sciences
  • Medicinal & Synthetic Chemistry
  • HitBuilder
  • LeadBuilder
  • CandidateBuilder

Quantifiable outcome

  • 18 clinical candidates since 2016
  • +6 more outcomes

Companies that use X-Chem

Customer profile

Named customers9 records

Segments5 records

Ideal customer profiles3 records

X-Chem technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature11 records

X-Chem partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered flagship, core and supporting.

  • Charles River LaboratoriesflagshipStrategic or Co-development Partner · 20 October 2025Strategic collaboration to enhance hit identification capabilities for drug discovery. Combines Charles River's existing drug discovery services with X-Chem's DNA-encoded library technology to support biopharma research and accelerate therapeutic discovery. Partnership aims to support hundreds of discovery programs.
  • ComInnexcoreOthers · 28 October 2021X-Chem acquired ComInnex, a European provider of synthetic chemistry services and technologies to support early-stage drug discovery. Acquisition expanded X-Chem's global capacity, service offerings, and expertise in innovative chemistry solutions for biopharma clients.
  • Glamorous AIcoreOthers · 28 October 2021X-Chem acquired Glamorous AI, adding the industry's only DEL-powered AI service for early-stage drug discovery to its portfolio.
  • IntelliSyn PharmacoreOthers · 1 January 2021X-Chem acquired IntelliSyn in January 2021, establishing hit-to-lead service capabilities including medicinal chemistry.
  • Montara TherapeuticscoreStrategic or Co-development PartnerCollaboration for neurological disease drug discovery. Leveraging brain-specific pharmacology platform, Montara works with X-Chem for next-generation therapies including dementia treatments. Based on successful prior collaboration with Mitokinin (acquired by AbbVie in 2023).
  • RochecoreTechnology or IntegrationDEL enablement partnership allowing Roche to operate DEL synthesis and screening internally. Roche/Genentech report indicated DEL accounted for ~30% of novel internally generated leads in 2019.
  • AstraZenecacoreTechnology or IntegrationLong-standing DEL collaboration with X-Chem screening many targets from AZ portfolio. Technology transfer enabled AZ to operate DEL synthesis and screening internally, providing flexibility for early-stage research deployment.
  • EnkocoreTechnology or IntegrationMulti-year collaboration culminating in successful technology enablement, empowering Enko to operate DEL platform internally. Projects have successfully progressed to include many high-potential products.
  • Structural Genomics Consortium (SGC)coreStrategic or Co-development PartnerCollaboration on ligand generation for WD40 repeat-containing proteins. Large-scale multiplexed DEL selection followed by ML model training identified active compounds for 7 out of 16 previously unliganded targets.
  • GooglecoreTechnology or IntegrationCollaboration using DEL data for machine learning published in August 2020. Combined DEL screening with ML for target class ligandability evaluation.
  • Relay TherapeuticscoreStrategic or Co-development PartnerCollaboration on WD40 repeat protein targets using DEL selection and machine learning approaches.
  • SymeressupportingStrategic or Co-development PartnerCollaboration on discovery and optimization of macrocycles targeting Mcl-1 oncology target, demonstrating acceptable permeability and high potency.
  • AbbViecoreStrategic or Co-development PartnerCollaboration on IL-17 inhibitors with DEL-generated SAR and co-crystal structural information leading to compound with good PK properties and potent animal model efficacy.
  • ArbutussupportingStrategic or Co-development PartnerCollaboration on development of noncovalent inhibitors for SARS-CoV-2 Mpro using DEL screening and macrocyclization strategy, achieving 10-fold potency improvement.
  • Texas A&M UniversitysupportingStrategic or Co-development PartnerDEL screening collaboration where hits demonstrated in vivo efficacy in mouse model for tuberculosis.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

X-Chem competitors and assessment

Company assessment

Emerging players

  • Carmot Therapeutics / BeBetter MedChem CROs: Smaller discovery CROs focused on fragment- and structure-based hit identification for biotech. Representative of the emerging-player tier of CROs that compete with X-Chem's HitBuilder and LeadBuilder programs on price for early-stage biotech.
  • Domainex: Domainex is a UK-based CRO offering integrated drug discovery including hit identification, medicinal chemistry and computational services. Comparable to X-Chem's integrated service model for biotech clients, particularly in the European market.

Direct peers

  • Symeres: Symeres is a European CRO specializing in medicinal chemistry, custom synthesis and discovery services. Comparable to X-Chem's medicinal and synthetic chemistry offering and an existing collaboration partner on macrocycle discovery programs.
  • HitGen: HitGen is the original DNA-encoded library (DEL) pioneer and operates a directly comparable DEL screening and small-molecule discovery services business, including DEL library products and partnered programs with global pharma. Most direct competitor to X-Chem's core DEL platform.
  • Philochem: Philochem is a Swiss-based DEL screening provider and one of the early commercial DEL technology developers. Competes head-to-head with X-Chem in DEL-based hit identification for European pharma and biotech clients.
  • Vipergen: Vipergen is a DEL-technology focused CRO offering DNA-encoded library screening and hit identification services to pharma and biotech. Closely comparable technology stack and customer base to X-Chem's DELcore and DELflex offerings.

Broad incumbents

  • Evotec: Evotec is a global drug discovery CRO offering end-to-end discovery and development services including DEL-based screening. Overlaps with X-Chem across hit identification, medicinal chemistry and integrated drug discovery but at much broader scale.
  • Nuevolution (Amgen): Nuevolution was an early DEL competitor acquired by Amgen in 2016; its DEL capability is now embedded inside Amgen's internal discovery engine. Relevant comparable because it demonstrates how DEL platforms are absorbed into large-pharma in-house operations, a key dynamic for X-Chem.
  • WuXi AppTec (HitSplice / DEL services): WuXi AppTec is a global CRO/CDMO offering DEL-enabled drug discovery alongside a much broader portfolio of chemistry, biology and manufacturing services. Overlaps with X-Chem in DEL screening but typically priced more aggressively and bundled with downstream development services.
  • Charles River Laboratories: Charles River is a large CRO with an end-to-end drug discovery and safety assessment portfolio and is now X-Chem's strategic distribution partner. Overlaps with X-Chem on early discovery services but also serves as a route to market for X-Chem's DEL platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

X-Chem social profiles

Digital presence

X-Chem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

X-Chem leadership team

Management profile

Number of profiles

Profiles10 records

X-Chem subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

X-Chem funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

X-Chem M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about X-Chem

What does X-Chem do?

X-Chem provides DNA-encoded library (DEL) screening-based drug discovery services combined with medicinal chemistry, computational sciences, and AI/ML capabilities. The company offers modular milestone-driven programs (HitBuilder, LeadBuilder, CandidateBuilder), fee-for-service packages (DELcore, DELflex, DELability), platform enablement technology transfers, and research products (ReadiDEL libraries, ReadiBLOX building blocks) to help pharmaceutical and biotechnology companies identify and optimize small molecule drug candidates from hit identification through clinical candidate nomination.

Is X-Chem a public or private company?

X-Chem is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was X-Chem founded?

X-Chem was founded in 2009. It employs 1 to 10 people.

Where is X-Chem based?

X-Chem is headquartered in Waltham, United States, in the North America region.

How does X-Chem make money?

Four revenue lines are on record. Drug Discovery Services are the primary driver. The others are strategic Collaborations, DEL Platform Enablement and research Products.

Who are X-Chem's main competitors?

Emerging players on record are Carmot Therapeutics / BeBetter MedChem CROs and Domainex. Direct peers are Symeres, HitGen, Philochem and Vipergen. Broad incumbents are Evotec, Nuevolution (Amgen), WuXi AppTec (HitSplice / DEL services) and Charles River Laboratories.

Does X-Chem have an API?

No public API is recorded for X-Chem.

What industry is X-Chem in?

X-Chem's product category is Contract Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 334516 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooX-Chem Announces Phase 3 Milestone in Collaboration with Relay TherapeuticsRelay Therapeutics initiated a Phase 3 clinical trial for zovegalisib, a PI3Ka inhibitor developed from an X-Chem DNA-encoded chemical library screen. The trial marks a milestone under the companies' collaboration agreement, with the drug showing mutant selectivity and a novel allosteric binding site.FinancialContent Business PageX-Chem Announces Phase 3 Milestone in Collaboration with Relay TherapeuticsRelay Therapeutics initiated a Phase 3 clinical trial for zovegalisib, an inhibitor of PI3Ka developed from an X-Chem DNA-encoded chemical library screen. The trial marks a milestone under the companies' collaboration agreement, with the drug showing mutant selectivity and a novel allosteric binding site.PharmafileSygnature formalises drug discovery collaboration with X-ChemSygnature Discovery formalized a collaboration with X-Chem to integrate DNA-encoded library screening into its drug discovery programmes. The partnership, which began in August 2026, provides DEL screening, selection science, and data analysis, alongside Sygnature's other hit-finding methods. The company said the choice of technology will depend on individual programme requirements.BioSpaceX-Chem Named First Winner of Chordoma Foundation TBXT Challenge with Discovery of Novel Binder for Untreatable Bone Cancer TargetX-Chem won the Chordoma Foundation's TBXT Challenge, becoming the first of 26 teams to discover a compound binding brachyury below 1 micromolar. The company received $100,000 in milestone awards for its DEL screening and computational approach. X-Chem will continue characterizing the compound for further TBXT-directed drug discovery.GlobeNewswireX-Chem Launches Chemomics: Applying Omics-Scale Chemistry Data to Yield New Candidate-Quality MoleculesX-Chem announced chemomics, a framework combining DNA-encoded library data with AI/ML to extract structure-activity insights. The approach uses billions of data points to generate predictive models and guide molecule design, with a launch reception in Boston on September 24.GlobeNewswireCube Biotech and X-Chem Partner to Enable DNA-encoded Library Screening of NativeMP™-stabilized Membrane ProteinsCube Biotech and X-Chem completed Project DEL-MP, proving DNA-encoded library screening works for membrane proteins stabilized with NativeMP copolymers. The collaboration validated hit discovery for targets like GLP1R, EGFR, and TNF, opening new drug discovery avenues.GlobeNewswireCube Biotech and X-Chem Partner to Enable DNA-encoded Library Screening of NativeMP™-stabilized Membrane ProteinsCube Biotech and X-Chem completed Project DEL-MP, proving that copolymer-stabilized membrane proteins can be screened with DNA-encoded libraries. The collaboration validated NativeMP technology for targets like GLP1R, EGFR, and TNF, enabling hit discovery for challenging targets.GlobeNewswireX-Chem Strengthens Executive Team with Strategic Finance and HR AppointmentsX-Chem appointed Stephen Fair as Chief Financial Officer and Maureen Hart as Senior Vice President of Human Resources. Fair brings nearly two decades of finance leadership, including at Abata Therapeutics, while Hart previously led HR at WuXi Biologics U.S. The appointments aim to support operational growth and discovery partnerships.GlobeNewswireX-Chem Expands Strategic Collaboration With Orion Pharma to Accelerate Orion’s Early Drug Discovery From Hit to CandidateX-Chem expanded its collaboration with Orion Pharma, extending the partnership from hit identification through to candidate selection under a new Technology Access Agreement. Orion will use X-Chem's DEL screening, AI-driven hit triage, and medicinal chemistry support to advance early-stage programs. The partnership aims to accelerate small molecule discovery with greater efficiency and precision.The Manila TimesX-Chem Expands Strategic Collaboration With Orion Pharma to Accelerate Orion's Early Drug Discovery From Hit to CandidateX-Chem expanded its collaboration with Orion Pharma, extending the partnership from hit identification through to candidate selection. Orion will use X-Chem's DEL screening, AI-driven hit triage, and medicinal chemistry support for multiple early-stage programs. The agreement aims to accelerate small molecule discovery with greater efficiency and precision.